Natural Beauty Bio-Technology Limited (0157) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Natural Beauty Bio-Technology Limited stock HK$0.08, price HK$0.43, that is 81.2% below the price, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range HK$0.4250 – HK$0.7058 · fair‑value band HK$0.0600 – HK$0.1100 · the HK$0.4250 price screens above the HK$0.0800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.
Follow Natural Beauty Bio-Technology in your weekly email
Every Wednesday you see whether Natural Beauty Bio-Technology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Natural Beauty Bio-Technology Limited, an investment holding company, provides skin care products and services in Mainland China, Taiwan, and internationally.
Show moreShow less
It manufactures and sells skin care, beauty, aroma-therapeutic, and make-up products, as well as health supplements under the Natural Beauty brand.
The company also offers skin treatments, beauty and spa services, medical cosmetology services, and skin care consulting and beauty training services, as well as beauty apparatus. In addition, its spas provide hydrotherapy, facial treatment, body care, and skin care analysis services.
Further, the company engages in the wholesale of skin care and beauty products. Natural Beauty Bio-Technology Limited was founded in 1976 and is based in Causeway Bay, Hong Kong.
Stock analysis
Natural Beauty Bio-Technology Limited (0157) currently trades at HK$0.4250, while our model-based Fair Value estimate is HK$0.0800, 81% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of HK$0.1500 per share, and 1 of the 12 models we run sit above the HK$0.4250 price.
Bear case: the Earnings-Based group reads lowest at HK$0.0700, and 11 of the 12 models stay below the price. Data coverage for this calculation is low.
Scenario range: HK$0.0600 (bear) to HK$0.1100 (bull), the price of HK$0.4250 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Consumer Defensive sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Natural Beauty Bio-Technology Limited reported revenue of HK$539M in FY2025 versus HK$488M in FY2021, a compound +2.5%/yr. Reported net income was HK$10.6M in FY2025, compounding −26.0%/yr from FY2021.
Key figures
Market cap HK$851M (≈ $109M) Micro · P/S ratio 1.72 · Net margin 2.0% · Return on equity −12.7% · Return on assets (EBIT) −1.5% (5-year average) · Operating margin −20.0% · Revenue (TTM) HK$523M · Revenue growth (YoY) −5.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (low confidence).
What moves the price
The share trades about 21% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −26% fair-value upside, at −81%, 0157 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (HK$0.0400 to HK$0.5000). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
BearHK$0.0600Fair Value HK$0.0800BullHK$0.1100
Price HK$0.4250 · Downside -81.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+52.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Start year 2020 (pandemic). Over 10 years: +0.6% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−13.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−13.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−13.5% vs −22.6%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → 4%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 3.5%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare Natural Beauty Bio-Technology Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 230 stocks
Beats the industry median on 0/9 measures
Overall it trails its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside−81.2% · Bottom 25%
Profitability
Return on assets1.1% · Below median
Net margin (12 months)−11.0% · Bottom 25%
Operating margin (12 months)−20.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−5.8% · Bottom 25%
Balance sheet
Debt / equity0.25× · Above median
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
P/B1.80× · Pricier than median
P/S (12 months)1.63× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 36
FUTURE (revenue growth)0· sector 20
PAST (return on equity)0· sector 31
HEALTH (low debt)88· sector 98
DIVIDEND (yield)0· sector 53
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Natural Beauty Bio-Technology Limited (0157) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of HK$0.0800 versus a price of HK$0.4250, about 81% lower (overvalued).
What is the fair value of 0157?
Our model-based fair value for Natural Beauty Bio-Technology Limited is HK$0.0800 (as of Nov 8, 2026), built from audited fundamentals. The current price: HK$0.4250.
What is the quality score of 0157?
Natural Beauty Bio-Technology Limited has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Natural Beauty Bio-Technology Limited (0157)?
Our model-based price target is the fair value of HK$0.0800 (as of Nov 8, 2026) from 12 valuation models. Cautious scenario HK$0.0600, optimistic scenario HK$0.1100. It is a calculation from audited fundamentals, not an analyst target.
What is the Natural Beauty Bio-Technology Limited stock forecast for 2026?
Our models put fair value at HK$0.0800, about 81% lower versus a price of HK$0.4250 (overvalued). Cautious scenario HK$0.0600, optimistic scenario HK$0.1100. The calculation is refreshed regularly with new filings.
What is the revenue of Natural Beauty Bio-Technology Limited (0157)?
Natural Beauty Bio-Technology Limited reported trailing-twelve-month revenue of about HK$523M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Natural Beauty Bio-Technology Limited (0157)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Natural Beauty Bio-Technology Limited it is HK$0.0800 per share (as of Nov 8, 2026), against a price of HK$0.4250. It is the blended result of 12 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Natural Beauty Bio-Technology Limited stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 0157 trades above its calculated fair value: price HK$0.4250, fair value HK$0.0800, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0157?
No. The price is what the market pays today (HK$0.4250); the fair value is what the company's own numbers justify (HK$0.0800). For Natural Beauty Bio-Technology Limited the two are HK$0.3450 per share apart. That gap is exactly why we show both numbers side by side.
How much is Natural Beauty Bio-Technology Limited worth?
The market values Natural Beauty Bio-Technology Limited at about HK$851M (market capitalisation, as of Nov 8, 2026). Per share that is HK$0.4250; our models calculate a fair value of HK$0.0800 per share.
What do the bullish and bearish scenarios say about 0157?
Our models span a range for Natural Beauty Bio-Technology Limited: cautious scenario HK$0.0600, base HK$0.0800, optimistic HK$0.1100 per share (as of Nov 8, 2026, price HK$0.4250). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Natural Beauty Bio-Technology Limited (0157)?
Balance-sheet figures for Natural Beauty Bio-Technology Limited (as of Nov 8, 2026): return on equity −12.7%, debt of 0.25 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 0157 from its 52-week high?
Natural Beauty Bio-Technology Limited trades at HK$0.4250, about 21% below its 52-week high of HK$0.5400 and at the low of HK$0.4250 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.0800 is for.
Which stocks are comparable to Natural Beauty Bio-Technology Limited?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Natural Beauty Bio-Technology Limited stock attractive at the current price?
The data as of Nov 8, 2026: price HK$0.4250, calculated fair value HK$0.0800 (−81%), Quality Score 50/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0157 calculated?
We run Natural Beauty Bio-Technology Limited through 12 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$0.0800 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Natural Beauty Bio-Technology Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Natural Beauty Bio-Technology Limited (0157)?
The closing price on Nov 6, 2026 was HK$0.4250. Our model-based fair value is HK$0.0800, about 81% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Natural Beauty Bio-Technology Limited right now?
The price sits above even our optimistic bull case (HK$0.1100). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (HK$0.0600 to HK$0.1100) leaves room in how you read the outcome.
Key figures of Natural Beauty Bio-Technology Limited
How large is the market capitalisation of Natural Beauty Bio-Technology Limited (0157)?
The market capitalisation of Natural Beauty Bio-Technology Limited is HK$851M (≈ $109M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Natural Beauty Bio-Technology Limited (0157)?
The price-to-sales ratio of Natural Beauty Bio-Technology Limited is 1.72 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Natural Beauty Bio-Technology Limited (0157)?
The net margin of Natural Beauty Bio-Technology Limited is 2.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Natural Beauty Bio-Technology Limited (0157)?
The return on equity (ROE) of Natural Beauty Bio-Technology Limited is −12.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Natural Beauty Bio-Technology Limited (0157)?
On an EBIT basis the return on assets of Natural Beauty Bio-Technology Limited is −1.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Natural Beauty Bio-Technology Limited (0157)?
The operating margin of Natural Beauty Bio-Technology Limited is −20.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Natural Beauty Bio-Technology Limited (0157)?
Revenue at Natural Beauty Bio-Technology Limited is growing −5.8% versus a year earlier (3y avg +17.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Natural Beauty Bio-Technology Limited (0157)?
Earnings per share at Natural Beauty Bio-Technology Limited are growing +28.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Natural Beauty Bio-Technology Limited (0157) generate?
The free cash flow of Natural Beauty Bio-Technology Limited is −HK$93.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Natural Beauty Bio-Technology Limited (0157) carry?
The net debt of Natural Beauty Bio-Technology Limited is HK$215M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Natural Beauty Bio-Technology Limited in the live analysis
One click puts Natural Beauty Bio-Technology Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026